Showing 4371-4380 of 4925 results for "".
- Antiperspirant, Deodorant Use Disrupts Microbiomehttps://practicaldermatology.com/news/antiperspirant-deodorant-use-disrupts-microbiome/2458718/Wearing antiperspirant or deodorant may influence the type and quantity of bacterial life found in the armpit's microbiome, new research suggests. "Using antiperspirant and deodorant completely rearranges the microbial ecosystem of your skin -- what's
- FDA Issues Consumer Warning about Crema Piel De Seda (Silky Skin Cream) by Viansilk: Risk of Mercury Poisoninghttps://practicaldermatology.com/news/fda-issues-consumer-warning-about-crema-piel-de-seda-silky-skin-cream-by-viansilk-risk-of-mercury-poisoning/2458725/The FDA warned consumers not to purchase or use a skin whitening cream called “Crema Piel De Seda,” due to the risk of mercury poisoning. FDA laboratory analysis identified mercury in the product. Exposure to mercury can cause serious health problems, such as kidney and nervous system
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Dr. Andrew Krakowski Now CMO at DermOnehttps://practicaldermatology.com/news/andrew-krakowski-now-cmo-at-dermone/2458729/Andrew C. Krakowski, MD has joined DermOne, a network of comprehensive dermatology practices, as Chief Medical Officer. “The need for dermatology services has accelerated in recent years, due to an aging population, a growing demand for surgical and cosmetic procedures and a raised
- Review Article Shines Spotlight on Neurocutaneous Disordershttps://practicaldermatology.com/news/review-article-shines-spotlight-on-neurocutaneous-disorders/2458739/There are at least 60 genetic neurocutaneous disorders that involve the skin, central nervous system, according to a review article in the Current Neurology and Neuroscience Reports. For example, neurofibrom
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha
- New World Market for Prescription Dermatological Drugs Report Releasedhttps://practicaldermatology.com/news/new-world-market-for-prescription-dermatological-drugs-report/2458749/Research and Markets recently added the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer,Melasma and Seborrhea Treatments)&qu
- Advancing Age May Affect Psoriasis Patients' Access to Biologicshttps://practicaldermatology.com/news/advancing-age-may-affect-psoriasis-patients-access-to-biologics/2458746/Elderly psoriasis patients may be less likely to receive biologics, according to a new study out of Umeå University in Sweden. Specifically, an age increase of 30 years resulted in an average 65 percent reduction in likelihood of obtaining treatment with biologics in this population
- Psoriasis Treatment Update: Rx Enstilar® Is Herehttps://practicaldermatology.com/news/psoriasis-treatment-update-rx-enstilaris-is-here/2458747/Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc., Enstilar